Portuguese-Canadian citizen originally from Viseu, Portugal. Bruno did his academic training in Scotland (United Kingdom); Bruno received his Master’s of Science in Molecular and Cellular Biology at the University of Glasgow (Glasgow, Scotland), from which he graduated with First Class Honours in 2003. He did his PhD in Biochemistry at the University of Dundee (Dundee, Scotland), graduating in 2008. He went on to do postdoctoral research work at the University of British Columbia (Vancouver, Canada) between 2008-2009 and at McGill University (Montréal, Canada) between 2009-2014. He became a research associate at Children’s Hospital of Eastern Ontario Research Institute (Ottawa, Canada) in 2014 (up until 2019). Bruno has produced 30 scientific publications (original articles, reviews and book chapters) totalizing over 3000 citations. Bruno is interested in drug development (early in his scientific career [2001-2002], Bruno worked as an intern at AstraZeneca Pharmaceuticals), particularly in the identification of mTOR inhibitors and their clinical application. Together with Dr. Rui Liu, he co-developed a free bioinformatic software repository for molecular biology tools called PrimerGenesis.
As the CEO of PrimerGen Ltd, Bruno is responsible for overseeing the basic scientific research and pre-clinical work of the company.
Born and raised in Lisbon, Raul has 7 years of experience in the financial and consulting industries. He started his career in BPI (Banco Português de Investimento), one of the largest banks in Portugal, where he was involved in the analysis and implementation of a new risk management system for the asset management division. Afterwards, he joined A.T. Kearney, a global strategic consulting firm, where he worked in several strategic projects for large corporations, both in Portugal and South Africa. Ultimately, Raul decided to engage in an innovative project, MFO | Multi Family Office, a concept that seeks the preservation of the family’s assets for present and future generations, where he is currently the Chief Economist. Raul always kept a strong connection with academia, and he is also currently working as a Teaching Assistant at NOVA School of Business and Economics, where he lectures mostly courses in finance both at the Bacherlor’s and Master’s levels. Raul holds a Master’s Degree in Finance and his Bachelor’s Degree in Management from NOVA School of Business and Economics. He received an award from Caixa Geral de Depósitos, the largest Portuguese bank, for ranking as the student with the highest GPA in his undergraduate program.
Raul completed the CFA, Chartered Financial Analyst program and he is, presently, actively engaged in several pro-bono projects with the CFA Portuguese society aimed at fostering financial literacy in the country.
As the CFO of PrimerGen Ltd, Raul is responsible for overseeing the corporate and financial aspects of the firm.
Portuguese-German citizen originally from Setúbal (Greater Lisbon Area), Portugal. Bruno Moraes completed his undergraduate studies in Biochemistry at the University of Lisbon (UL, Portugal) in 2008. He received his Master’s Degree in Medical Biochemistry at the UL in 2010, with work done in the field of Cystic Fibrosis (Pulmonary Disease), having written a dissertation entitled “Study of CFTR delivery and stabilization at the plasma membrane” based on his research conducted at the National Institute of Health Dr. Ricardo Jorge (Lisbon, Portugal). Bruno Moraes is currently finishing his PhD from the GABBA Program at the Abel Salazar Biomedical Sciences Institute at the University of Porto. Throughout his doctoral studies, Bruno did various internships in a number of international academic institutions including McGill University (Montréal, Canada) and The University of Edinburgh (Scotland, United Kingdom) where he researched basic mechanisms of learning and memory formation. In recent years, he has carried out work on neurodegenerative diseases at the Center for Neuroscience and Cell Biology, University of Coimbra (Portugal). As a Scientific Consultant, Bruno advises the company on scientific matters.
Portuguese citizen originally from Lisbon Portugal. Inês Cabrita completed her undergraduate studies in Biochemistry at the University of Lisbon (UL, Portugal) in 2013. She received her Master’s Degree in Medical Biochemistry at the UL in 2015, with work done in the study of calcium modulation by chloride channels having written a dissertation entitled “Anoctamins, a novel family of ion channels and their role in intracellular calcium signaling” based on her research conducted at the University of Regensburg (Regensburg, Germany).
Inês Cabrita received her PhD from the Institute of Physiology at the University of Regensburg in Regensburg, Germany.
Throughout her doctoral studies, Inês researched the therapeutic potential of TMEM16 inhibitors for the treatment of Polycystic Kidney Disease, Asthma and Cystic Fibrosis.
As the Chief Scientific Officer of PrimerGen Ltd, Inês Cabrita is responsible for overseeing the scientific procedural work of the company.
Portuguese citizen originally from Viseu, Portugal. At the age of 13, Teresa moved from Portugal to the United Kingdom – where she has been residing since. She is currently completing her year 13 (final year of Sixth Form), at the end of which she will receive her International Baccalaureate (IB) qualification. Prior to this, Teresa earned eleven GCSE’s and participated in various volunteering activities in both the medical and science fields. In the future, Teresa aims to pursue a medical career.
Teresa is a Pre-Medical Intern at Primergen Ltd. She is responsible for assisting with clinical trial data analysis, science literature search and medical treatment options for COVID-19 research.
We are a team of talented young scientists, medical doctors and financial analysts dedicated to the pursuit of the development of a treatment for COVID-19 and other opportunistic viral infections.
T: +351 916 817 150
© 2020 PrimerGen Ltd. | Design by CIGA
All rights reserved PrimerGen Ltd.